Veracyte (San Francisco, CA) a clinical-stage molecular diagnostics company focused on non-small cell lung cancer and thyroid cancers, closed a $28M Series B financing. Participants include Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures.